An Open-label, Randomized Two-arm Parallel Group Study to Compare the Effects of 4-week QD Treatment With Lixisenatide or Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin

The purpose of the study is to compare the pharmacodynamic effects of lixisenatide (AVE0010),
in comparison to liraglutide, as an add-on treatment to metformin, over a period of 4 weeks
of treatment.

The primary objective is to assess the effects of lixisenatide, in comparison to liraglutide,
in reducing postprandial plasma glucose (PPG) assessed as area under the plasma glucose
concentration curve (AUC) after a standardized breakfast at Week 4.

The secondary objectives are to assess the effects of lixisenatide on the maximum PPG
excursion, and on the changes in insulin, pro-insulin, C-peptide and glucagon plasma
concentrations following a standardized breakfast, 24-hour profile of plasma glucose,
glycosylated hemoglobin (HbA1c), satiety markers (obestatin, peptide YY [PYY3-36] and
oxyntomodulin); and to assess the clinical and laboratory safety profile.